(Q38066786)

28 August 2017

1 reference

title

Genetic and epigenetic alterations of myeloproliferative disorders (English)

1 reference

28 August 2017

2

1 reference

28 August 2017

Jelena D Milosevic

1

1 reference

28 August 2017

12 December 2012

1 reference

International Journal of Hematology

28 August 2017

1 reference

28 August 2017

97

1 reference

28 August 2017

2

1 reference

28 August 2017

183-197

1 reference

https://scigraph.springernature.com/pub.10.1007/s12185-012-1235-2

28 August 2017

0 references

cites work

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

New mutations and pathogenesis of myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Hematopoietic cytokine receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

HP1alpha guides neuronal fate by timing E2F-targeted genes silencing during terminal differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Heterochromatin protein 1 is recruited to various types of DNA damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

LNK mutations in JAK2 mutation-negative erythrocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Flt3-dependent transformation by inactivating c-Cbl mutations in AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

The Cbl interactome and its functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Ubiquitination and degradation of the thrombopoietin receptor c-Mpl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

The E3 ubiquitin ligase c-Cbl restricts development and functions of hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Clinical significance of genetic aberrations in secondary acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Frequent pathway mutations of splicing machinery in myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

The role of mutations in epigenetic regulators in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Mutation in TET2 in myeloid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Extent of hematopoietic involvement by TET2 mutations in JAK2V⁶¹⁷F polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Taxing sugar-sweetened beverages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

DNMT3A Mutations in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Mutational analysis of the catalytic domain of the murine Dnmt3a DNA-(cytosine C5)-methyltransferase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Dnmt3a is essential for hematopoietic stem cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Isolation and characterization of a novel H1.2 complex that acts as a repressor of p53-mediated transcription.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Mutations of ASXL1 gene in myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Role of histone H3 lysine 27 methylation in Polycomb-group silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

EZH2 mutational status predicts poor survival in myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Genetic complexity of myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Identification of new translocations involving ETV6 in hematologic malignancies by fluorescence in situ hybridization and spectral karyotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Molecular pathogenesis of Philadelphia chromosome negative chronic myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

AML transformation in 56 patients with Ph- MPD in two well defined populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Ikaros dominant negative isoform (Ik6) induces IL-3-independent survival of murine pro-B lymphocytes by activating JAK-STAT and up-regulating Bcl-xl levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

p110 CUX1 cooperates with E2F transcription factors in the transcriptional activation of cell cycle-regulated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Transgenic mice expressing the p75 CCAAT-displacement protein/Cut homeobox isoform develop a myeloproliferative disease-like myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

CUX1 transcription factor is required for optimal ATM/ATR-mediated responses to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

A patient with a 20-year lag phase between JAK2-V617F+ myeloproliferation and NPM1-mutated AML arguing against a common origin of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Role of germline genetic factors in MPN pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

Germline JAK2 mutation in a family with hereditary thrombocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1235-2

The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p.

21 January 2018

1 reference

12 December 2020

Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression

1 reference

12 December 2020

Acquired resistance to interferon alpha therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofibrosis

1 reference

12 December 2020

Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders

1 reference

12 December 2020

SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients

1 reference

12 December 2020

DNMT3A mutations in myeloproliferative neoplasms

1 reference

12 December 2020

Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F

1 reference

12 December 2020

Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease Anticipation

1 reference

12 December 2020

Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders

1 reference

12 December 2020

Rare germline variants in regions of loss of heterozygosity may influence clinical course of hematological malignancies

1 reference

12 December 2020

p53 lesions in leukemic transformation

1 reference

12 December 2020

Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias

1 reference

12 December 2020

High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21

1 reference

12 December 2020

Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms

1 reference

12 December 2020

SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival

1 reference

12 December 2020

Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene

1 reference

12 December 2020

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

12 December 2020

Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias

1 reference

12 December 2020

Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms

1 reference

12 December 2020

A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera

1 reference

12 December 2020

The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera

1 reference

12 December 2020

SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts

1 reference

12 December 2020

10.1007/S12185-012-1235-2

Identifiers

DOI

1 reference

PubMed ID

23233154

Dimensions Publication ID

28 August 2017

0 references

1 reference

PubMed ID

23233154